Transforming growth factor-β and ischemic brain injury

被引：84

作者：

Alain Buisson ^{[1
]}

Sylvain Lesne ^{[1
]}

Fabian Docagne ^{[1
]}

Carine Ali ^{[1
]}

Olivier Nicole ^{[1
]}

Eric T. MacKenzie ^{[1
]}

Denis Vivien ^{[1
]}

机构：

[1] Université de CAEN, UMR CNRS 6551, Centre CYCERON, Caen Cedex, bd H. Becquerel

[2] Universite de CAEN-CNRS UMR 6551, Centre CYCERON, IFR 47

来源：

Cellular and Molecular Neurobiology | 2003年 / 23卷 / 4-5期

关键词：

Cerebral ischemia; Molecular; TGF-β;

D O I：

10.1023/A:1025072013107

中图分类号：

学科分类号：

摘要：

1. Necrosis and apoptosis are the two fundamental hallmarks of neuronal death in stroke. Nevertheless, thrombolysis, by using the recombinant serine protease t-PA, remains until now the only approved treatment of stroke in man. 2. Over the last years, the cytokine termed Transforming Growth Factor-β1 (TGF-β1) has been found to be strongly up-regulated in the central nervous system following ischemia-induced brain damage. 3. Recent studies have shown a neuroprotective activity of TGF-β1 against ischemia-induced neuronal death. In vitro, TGF-β1 protects neurons against excitotoxicity by inhibiting the t-PA-potentiated NMDA-induced neuronal death through a mechanism involving the up-regulation of the type-1 plasminogen activator inhibitor (PAI-1) in astrocytes. 4. In addition, TGF-β1 has been recently characterized as an antiapoptotic factor in a model of staurosporine-induced neuronal death through a mechanism involving activation of the extracellular signal-regulated kinase 1/2 (Erk1/2) and a concomitant increase phosphorylation of the antiapoptotic protein Bad. 5. Altogether, these observations suggest that either TGF-β signaling or TGF-β1-modulated genes could be good targets for the development of new therapeutic strategies for stroke in man.

引用

页码：539 / 550

页数：11

共 53 条

[31] Pinkoski M.J., Green D.R., Fas ligand, death gene, Cell Death Differ., 6, pp. 1174-1181, (1999)
[32] Prehn J.H., Backhauss C., Krieglstein J., Transforming growth factor-β1 prevents glutamate neurotoxicity in rat neocortical cultures and protects mouse neocortex from ischemic injury in vivo, J. Cereb. Blood Flow Metab., 3, pp. 521-525, (1993)
[33] Prehn J.H., Bindokas V.P., Marcuccilli C.J., Krajewski S., Reed J.C., Miller R.J., Regulation of neuronal Bcl2 protein expression and calcium homeostasis by transforming growth factor type-β confers wide-ranging protection on rat hippocampal neurons, Proc. Natl. Acad. Sci. U.S.A., 91, pp. 12599-12603, (1994)
[34] Prehn J.H., Miller R.J., Opposite effects of TGF-β 1 on rapidly- and slowly-triggered excitotoxic injury, Neuropharmacology, 35, pp. 249-256, (1996)
[35] Raff M.C., Barres B.A., Burne J.F., Coles H.S., Ishizaki Y., Jacobson M.D., Programmed cell death and the control of cell survival: Lessons from the nervous system, Science, 262, pp. 695-700, (1993)
[36] Rogister B., Leprince P., Delree P., Van Damme J., Billiau A., Moonen G., Enhanced release of plasminogen activator inhibitor(s) but not of plasminogen activators by cultured rat glial cells treated with interleukin-1, Glia, 3, pp. 252-257, (1990)
[37] Rogister B., Leprince P., Pettmann B., Labourdette G., Sensenbrenner M., Moonen G., Brain basic fibroblast growth factor stimulates the release of plasminogen activators by newborn rat cultured astroglial cells, Neurosci. Lett., 91, pp. 321-326, (1988)
[38] Rosenbaum D.M., Gupta G., D'Amore J., Singh M., Weidenheim K., Zhang H., Kessler J.A., Fas (CD95/APO-1) plays a role in the pathophysiology of focal cerebral ischemia, J. Neurosci. Res., 61, pp. 686-692, (2000)
[39] Ruocco A., Nicole O., Docagne F., Ali C., Chazalviel L., Komesli S., Yablonsky F., Roussel S., MacKenzie E.T., Vivien D., Buisson A., A transforming growth factor-beta antagonist unmasks the neuroprotective role of this endogenous cytokine in excitotoxic and ischemic brain injury, J. Cereb. Blood Flow Metab., 19, pp. 1345-1353, (1999)
[40] Schneider P., Tschopp J., Apoptosis induced by death receptors, Pharm. Acta. Helv., 74, pp. 281-286, (2000)

← 1 2 3 4 5 6 →